Evidence map›Paper›PMID 31552546›Full record

ArticleInflammopharmacology2020

Dendritic cells generated in the presence of interferon-α and modulated with dexamethasone as a novel tolerogenic vaccine platform.

Olga Leplina, Yulia Kurochkina, Marina Tikhonova, Ekaterina Shevela, Alexandr Ostanin, Elena Chernykh

Abstract read
PubMed Publisher
In one paragraph

Article in Inflammopharmacology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact, top 89% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Olga LeplinaResearch Institute of Fundamental and Clinical Immunology, Yadrintsevskaya Str., 14, Novosibirsk, Russian Federation, 630099. oleplina@mail.ru.ORCID http://orcid.org/0000-0003-3169-8643
Yulia KurochkinaResearch Institute of Fundamental and Clinical Immunology, Yadrintsevskaya Str., 14, Novosibirsk, Russian Federation, 630099.ORCID http://orcid.org/0000-0002-7080-777X
Marina TikhonovaResearch Institute of Fundamental and Clinical Immunology, Yadrintsevskaya Str., 14, Novosibirsk, Russian Federation, 630099.ORCID http://orcid.org/0000-0002-2366-1667
Ekaterina ShevelaResearch Institute of Fundamental and Clinical Immunology, Yadrintsevskaya Str., 14, Novosibirsk, Russian Federation, 630099.ORCID http://orcid.org/0000-0001-8997-3586
Alexandr OstaninResearch Institute of Fundamental and Clinical Immunology, Yadrintsevskaya Str., 14, Novosibirsk, Russian Federation, 630099.ORCID http://orcid.org/0000-0001-6895-938X
Elena ChernykhResearch Institute of Fundamental and Clinical Immunology, Yadrintsevskaya Str., 14, Novosibirsk, Russian Federation, 630099.ORCID http://orcid.org/0000-0003-2346-6279
Research Institute of Fundamental and Clinical Immunology · RU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundTolerogenic dendritic cells (tDCs) are considered a novel therapeutic tool in treating autoimmune diseases, allergies, and transplantation reactions. Among numerous pharmacological immune modulators, dexamethasone (Dex) is known to induce potent tolerogenicity in DCs generated from human monocytes with granulocyte-macrophage colony-stimulating factor (GM-CSF) and interleukin-4 (IL-4), and these cells (IL-4-DCs/Dex) are being appraised as a tDC-based platform in clinical settings. Interferon-α (IFNα) represents another powerful inducer of monocyte-derived DCs, which possess higher migratory activity and stability. However, the functions of IFN-DCs/Dex have not been sufficiently analyzed and there are no comparative studies of the tolerogenicity of IFN-DCs/Dex and IL-4-DCs/Dex. This study aimed to investigate the properties of IFN-DCs/Dex in comparison with IL-4-DCs/Dex.

resultsDCs were obtained by cultivation of an adherent fraction of peripheral blood mononuclear cells (MNCs) in the presence of GM-CSF and IFNα or IL-4 with subsequent lipopolysaccharide-driven maturation. Dex (10

conclusionsThe data obtained indicate that potent tDCs could be generated by treating IFN-DCs with dexamethasone. The tolerogenic properties of IFN-DCs/Dex are better than or at least equal to those of the IL-4-DCs/Dex, as assessed by in vitro phenotypic and functional assays, suggesting these cells as a new tolerogenic vaccine platform.

Indexed as

Antigens, CDCells, CulturedCytokinesDendritic CellsDexamethasoneHumansInflammationInterferon-alphaInterleukin-10Leukocytes, MononuclearLymphocyte ActivationTh1 CellsTumor Necrosis Factor-alphaVaccinesAntigens, CDCytokinesDexamethasoneInterferon-alphaInterleukin-10Tumor Necrosis Factor-alphaVaccinesAllostimulatory activityCytokinesDendritic cellsDexamethasoneInterferon-αPhenotypical characteristicTolerogenic properties

Identifiers

PMID31552546
OpenAlexW2976651860

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.